MX386151B - Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. - Google Patents

Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.

Info

Publication number
MX386151B
MX386151B MX2016002308A MX2016002308A MX386151B MX 386151 B MX386151 B MX 386151B MX 2016002308 A MX2016002308 A MX 2016002308A MX 2016002308 A MX2016002308 A MX 2016002308A MX 386151 B MX386151 B MX 386151B
Authority
MX
Mexico
Prior art keywords
multiple myeloma
trichostatin
tsa
treatment
individual
Prior art date
Application number
MX2016002308A
Other languages
English (en)
Other versions
MX2016002308A (es
Inventor
Christian Lavedan
Louis William Licamele
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2016002308A publication Critical patent/MX2016002308A/es
Publication of MX386151B publication Critical patent/MX386151B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Navigation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere en general al tratamiento del mieloma múltiple. Una modalidad de la invención proporciona un método para tratar el mieloma múltiple (MM) en un individuo, comprendiendo el método: administrar al individuo una cantidad eficaz de tricostatina A (TSA).
MX2016002308A 2013-08-22 2014-08-22 Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. MX386151B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
US201361870747P 2013-08-27 2013-08-27
PCT/US2014/052216 WO2015027125A1 (en) 2013-08-22 2014-08-22 Multiple myeloma treatment

Publications (2)

Publication Number Publication Date
MX2016002308A MX2016002308A (es) 2016-06-15
MX386151B true MX386151B (es) 2025-03-18

Family

ID=51492478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002308A MX386151B (es) 2013-08-22 2014-08-22 Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.

Country Status (13)

Country Link
US (5) US20160199324A1 (es)
EP (2) EP3623011B1 (es)
JP (4) JP2016534115A (es)
KR (6) KR102465000B1 (es)
CN (2) CN105579100A (es)
AU (1) AU2014308704B2 (es)
BR (1) BR112016003609B1 (es)
CA (2) CA3171302A1 (es)
CL (2) CL2016000396A1 (es)
EA (1) EA037638B1 (es)
ES (2) ES2754199T3 (es)
MX (1) MX386151B (es)
WO (1) WO2015027125A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3623011B1 (en) 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
CN109913420A (zh) * 2019-03-07 2019-06-21 北京师范大学 Cdc20共表达基因网络作为胶质瘤治疗靶点的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO2002060430A1 (en) 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
EP1638541B1 (en) 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
EP1766086A4 (en) * 2004-05-21 2009-10-28 Univ Arkansas USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
KR20090014393A (ko) * 2006-05-26 2009-02-10 셀진 코포레이션 조합 요법에서 면역조절 화합물을 사용하는 방법 및 조성물
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20110301055A1 (en) * 2008-12-05 2011-12-08 Nicholas James Dickens Methods for determining a prognosis in multiple myeloma
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2013071247A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
EP2602330A1 (en) 2011-12-07 2013-06-12 Palacky University, Olomouc Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
EP3623011B1 (en) 2013-08-22 2025-02-12 Vanda Pharmaceuticals Inc. Trichostatin a for use in multiple myeloma treatment
JP2016528297A (ja) * 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
DE102014117278A1 (de) 2014-11-25 2016-05-25 Krones Ag Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage

Also Published As

Publication number Publication date
US12673033B2 (en) 2026-07-07
MX2016002308A (es) 2016-06-15
KR20220035275A (ko) 2022-03-21
US20180256521A1 (en) 2018-09-13
US20160199324A1 (en) 2016-07-14
ES3018607T3 (es) 2025-05-16
JP2020073508A (ja) 2020-05-14
EP3623011A1 (en) 2020-03-18
JP7698680B2 (ja) 2025-06-25
CN113244205A (zh) 2021-08-13
KR20210021602A (ko) 2021-02-26
BR112016003609B1 (pt) 2021-04-27
AU2014308704B2 (en) 2019-10-10
US20200009087A1 (en) 2020-01-09
EA201690446A1 (ru) 2016-06-30
KR20160033780A (ko) 2016-03-28
EA037638B1 (ru) 2021-04-23
US11737993B2 (en) 2023-08-29
KR20200011554A (ko) 2020-02-03
KR102373721B1 (ko) 2022-03-11
EP3623011B1 (en) 2025-02-12
CA2921037C (en) 2022-11-15
KR20220153684A (ko) 2022-11-18
ES2754199T3 (es) 2020-04-16
CL2018001719A1 (es) 2018-07-27
JP2023179435A (ja) 2023-12-19
NZ716669A (en) 2021-03-26
US20240342120A1 (en) 2024-10-17
CN105579100A (zh) 2016-05-11
CA2921037A1 (en) 2015-02-26
US20230346719A1 (en) 2023-11-02
JP2022017337A (ja) 2022-01-25
AU2014308704A1 (en) 2016-02-25
CL2016000396A1 (es) 2017-03-17
WO2015027125A1 (en) 2015-02-26
EP3036006A1 (en) 2016-06-29
CA3171302A1 (en) 2015-02-26
JP2016534115A (ja) 2016-11-04
EP3036006B1 (en) 2019-10-09
KR20170126019A (ko) 2017-11-15
KR102465000B1 (ko) 2022-11-09

Similar Documents

Publication Publication Date Title
PH12015502075A1 (en) Treatment of cataplexy
MX386598B (es) Compuestos antibacterianos.
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX380689B (es) Tratamiento de cancer con dihidropirazino-pirazinas.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201591399A1 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201692534A1 (ru) Способы лечения гипотонии
CR20160282A (es) Quinazolin-thf-aminas como inhibidores de pde1
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
MX2020011946A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
CL2018001719A1 (es) Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)
AR102871A1 (es) Métodos de tratamiento de fibrosis
BR112016012248A2 (pt) método de tratamento de nefropatia
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
EA201491581A1 (ru) Везикулярные композиции
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
MX374354B (es) Método de curación de heridas.
BR112016014099A2 (pt) método de tratamento de feridas
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии